Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery.
about
Degradation and Stabilization of Peptide Hormones in Human Blood SpecimensSerum apolipoproteins C-I and C-III are reduced in stomach cancer patients: results from MALDI-based peptidome and immuno-based clinical assaysThrombin induces broad spectrum proteolysis in human serum samples.Differential exoprotease activities confer tumor-specific serum peptidome patternsThe use of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry to detect putative breast cancer markers in saliva: a feasibility study.MALDI-TOF serum protein profiling for the detection of breast cancer.Automated serum peptide profiling.A sequence-specific exopeptidase activity test (SSEAT) for "functional" biomarker discovery.Liquid chromatography/tandem mass spectrometric method for the quantification of eight proteolytic fragments of ITIH4 with biomarker potential in human plasma and serum.Prion disease diagnosis by proteomic profiling.Proteomic analyses of pancreatic cyst fluidsHigh-throughput and targeted in-depth mass spectrometry-based approaches for biofluid profiling and biomarker discovery.Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer.Circulating proteolytic products of carboxypeptidase N for early detection of breast cancerInvestigation of an albumin-enriched fraction of human serum and its albuminome.Proteomic profiling of uremia in serum using magnetic bead-based sample fractionation and MALDI-TOF MS.Strategy for degradomic-peptidomic analysis of human blood plasmaQuantitative peptidomic analysis by a newly developed one-step direct transfer technology without depletion of major blood proteins: its potential utility for monitoring of pathophysiological status in pregnancy-induced hypertension.Top-down label-free LC-MALDI analysis of the peptidome during neural progenitor cell differentiation reveals complexity in cytoskeletal protein dynamics and identifies progenitor cell markers.A pilot study to investigate the potential of mass spectrometry profiling in the discovery of novel serum markers in chronic renal disease.Preparation of magnetic core-mesoporous shell microspheres with C8-modified interior pore-walls and their application in selective enrichment and analysis of mouse brain peptidome.High throughput profiling of serum phosphoproteins/peptides using the SELDI-TOF-MS platformFunctional protease profiling for diagnosis of malignant disease.The Use of Principal Component Analysis in MALDI-TOF MS: a Powerful Tool for Establishing a Mini-optimized Proteomic ProfileMS/MS library facilitated MRM quantification of native peptides prepared by denaturing ultrafiltration.Proteomic profiling of nephrotic syndrome in serum using magnetic bead based sample fractionation & MALDI-TOF MS.Urine Peptidomic and Targeted Plasma Protein Analyses in the Diagnosis and Monitoring of Systemic Juvenile Idiopathic Arthritis.Specific Investigation of Sample Handling Effects on Protease Activities and Absolute Serum Concentrations of Various Putative Peptidome Cancer Biomarkers.Serum peptidome patterns of colorectal cancer based on magnetic bead separation and MALDI-TOF mass spectrometry analysisPermeation through phospholipid bilayers, skin-cell penetration, plasma stability, and CD spectra of α- and β-oligoproline derivatives.Mechanistic peptidomics: factors that dictate specificity in the formation of endogenous peptides in human milk.An extensive targeted proteomic analysis of disease-related protein biomarkers in urine from healthy donors.Comprehensive quantitative analysis of ovarian and breast cancer tumor peptidomes.Carboxypeptidase N-deficient mice present with polymorphic disease phenotypes on induction of experimental autoimmune encephalomyelitis.Mass spectrometry-based serum peptide profiling in hepatocellular carcinoma with bone metastasis.Cancer and the microbiome: potential applications as new tumor biomarker.Phenotype-Driven Plasma Biobanking Strategies and Methods-The advancement of biomarker-based diagnostic tools for ovarian, breast, and pancreatic cancer through the use of urine as an analytical biofluid.Global stability of plasma proteomes for mass spectrometry-based analyses.Current status and prospects of clinical proteomics studies on detection of colorectal cancer: hopes and fears.
P2860
Q28546842-D85038C4-A25A-40A5-A78B-AA6A2D54B1DAQ28743469-2FB36BDF-F14C-47A6-AE56-910CDC48D393Q30855514-DDFA9A7E-8FED-4650-BE6E-3E537062B8B7Q33230965-2AB53407-BFB6-475B-AAF7-CF2C9C50D858Q33240656-F65759B0-B2FB-4689-918C-811FA13ECD5DQ33261717-4D3B9B73-B4C5-4C1E-B307-CC1EF1EE592AQ33280949-544E7F02-0004-4CF0-8665-04FEFE89FED0Q33305170-265DE146-D96F-41E7-B18A-FFDA5884E744Q33364206-6A25CDA6-B516-404E-A093-AC7C8CEC5EC4Q33398738-77E8F0AE-0130-40BD-B199-7FDF880CB022Q33399055-2CDA3091-B98A-4F09-8D52-B7181FEA22B8Q33579375-666570E6-049C-42C3-AF97-95AD1E594A8BQ33597715-EADB355F-1A7F-4057-87B7-67770CCCE233Q33685829-F3CBEA20-F8C9-447C-A493-4BA82A39D19FQ33701508-C1C38DBC-73A0-4779-87E8-DD60ABEB7414Q33721224-E798A6D2-C2F1-43CC-B7BF-BD3EE4C59CDCQ33835867-7AEAF5FA-2E08-4B72-AD71-B50E97540A11Q33918651-497CE6B9-63B9-437A-A39D-D7E381177E4EQ33962226-B19DA67C-7C61-4B92-9A82-FCC7501607FCQ33990550-8C30542F-6FE5-4DF1-BCC7-AC442803C77CQ34014727-0AA86BC4-B8C4-4FE2-BDAA-BA7ABF927EE4Q34074494-BA91051B-0501-4816-B759-285416AEDB61Q34116114-775F6817-E493-47E9-B837-860688643739Q34121793-901F440A-8948-4B1E-85D8-D867CFEA6DD7Q34150493-075EF043-47EE-42E6-B5BD-9F1A2F00B60DQ34259029-68CA3D1F-C18A-4A7E-81A8-8CD1125BF847Q34268714-FBFE7EDE-643A-4847-9A03-4D113B2FEB95Q34268788-9FFB9FC0-697F-461B-B7DF-9F676E3D8647Q34454987-2114B806-11C3-4E60-AD7F-E9BE725C7EF4Q34557817-7ABB7166-3815-4342-B467-0B4DDFFA0DA2Q34634913-F10C4614-E7E1-48CD-8C85-3BCD14199600Q34749242-73FD78D7-6DBE-475D-AABE-7E5423E70BBDQ34855337-B3DE63C4-5CBD-448A-872B-C359FEC61B07Q35116383-BD3E3523-15DC-4056-8244-0C2461090D88Q35128558-E87CA5F4-9A92-463A-BA64-E35088FFF80BQ35508820-AB50D947-C335-41B5-BE74-EB0A4A858C23Q35674060-9F4340C3-660C-45A0-A00D-CD62887CFF66Q36016842-E8117389-672B-445B-82A7-83DBF1A65340Q36208968-4F8EE249-88B8-4A75-ACF7-81CE047E2421Q36640047-FAABB1E2-737F-4B95-A18C-026691846296
P2860
Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Direct tandem mass spectrometr ...... or plasma biomarker discovery.
@ast
Direct tandem mass spectrometr ...... or plasma biomarker discovery.
@en
type
label
Direct tandem mass spectrometr ...... or plasma biomarker discovery.
@ast
Direct tandem mass spectrometr ...... or plasma biomarker discovery.
@en
prefLabel
Direct tandem mass spectrometr ...... or plasma biomarker discovery.
@ast
Direct tandem mass spectrometr ...... or plasma biomarker discovery.
@en
P2093
P356
P1476
Direct tandem mass spectrometr ...... or plasma biomarker discovery.
@en
P2093
Donghui Li
James Abbruzzese
John M Koomen
Lian-chun Xiao
Ryuji Kobayashi
Thomas C Liu
P304
P356
10.1021/PR050046X
P577
2005-05-01T00:00:00Z